RxDoctor Payments Data

Vinod Assomull, MD

Nephrology · Granada Hills, CANPI 1982619359

Payments from drug & device makers

$352,291in general payments, 2019–2025

Across 69 payments — averaging $5105.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$211K
  • Beone Medicines Ltd.$79K
  • CSL Behring$38K
  • Takeda Pharmaceuticals U.S.A., Inc.$23K
  • Novartis$713
  • Boehringer Ingelheim$180
  • plus $729 from 12 others

What the payments were for

  • Food & beverage$1,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$352,291 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$19,202
Medicare patients
26
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide178$193,674
KerendiaFinerenone108$85,116
JardianceEmpagliflozin71$83,972
MounjaroTirzepatide25$33,976
Lanthanum Carbonate15$24,131
ClinolipidFat Emulsion/Olive/Soy/Phospho71$23,009
RybelsusSemaglutide13$22,584
VeltassaPatiromer Calcium Sorbitex24$20,277
RenvelaSevelamer Carbonate13$19,805
AuryxiaFerric Citrate11$17,281
LokelmaSodium Zirconium Cyclosilicate17$13,786
ProsolParenteral Amino Acid 20% No.154$6,674
Sevelamer Carbonate25$6,152
Calcium Acetate20$2,067
Nifedipine ErNifedipine44$1,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$38$216,258191 claims
Boehringer IngelheimJardiance$180$83,97271 claims
Lilly USA, LLCMounjaro$60$33,97625 claims
AstraZenecaLokelma$14$13,78617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in Granada Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →